Bjarke M. Klein

Reply of the Authors: Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.

Journal: Fertility and sterility

Published: January 05, 2024

Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight.

Journal: Reproductive biomedicine online

Published: March 30, 2021

Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.

Journal: Fertility and sterility

Published: July 22, 2020

Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles.

Journal: Reproductive biomedicine online

Published: May 28, 2018

Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial.

Journal: Reproductive biomedicine online

Published: March 01, 2018

Luteal phase progesterone and oestradiol after ovarian stimulation: relation to response and prediction of pregnancy.

Journal: Reproductive biomedicine online

Published: July 04, 2017

Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.

Journal: Fertility and sterility

Published: September 15, 2016

Follicular and endocrine dose responses according to anti-Müllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049).

Journal: Clinical endocrinology

Published: June 03, 2015

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials.

Journal: Fertility and sterility

Published: October 10, 2014

Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Journal: Fertility and sterility

Published: April 11, 2014

The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin.

Journal: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Reply of the Authors: Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.

Reply of the Authors: Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.

Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight.

Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight.

Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.

Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.

Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles.

Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles.

Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial.

Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial.

Luteal phase progesterone and oestradiol after ovarian stimulation: relation to response and prediction of pregnancy.

Luteal phase progesterone and oestradiol after ovarian stimulation: relation to response and prediction of pregnancy.

Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.

Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.

Follicular and endocrine dose responses according to anti-Müllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049).

Follicular and endocrine dose responses according to anti-Müllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049).

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials.

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials.

Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin.

The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin.

Reply of the authors.

Reply of the authors.